A detailed history of Nine Point Two Capital LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Nine Point Two Capital LLC holds 12,147 shares of NTLA stock, worth $178,803. This represents 0.15% of its overall portfolio holdings.

Number of Shares
12,147
Holding current value
$178,803
% of portfolio
0.15%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $281,324 - $392,833
12,147 New
12,147 $370,000
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $213,566 - $284,281
6,176 New
6,176 $251,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.12B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Nine Point Two Capital LLC Portfolio

Follow Nine Point Two Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nine Point Two Capital LLC with notifications on news.